Oncotarget is a bio-medical journal established in 2010 that publishes articles and studies done by the most prominent cancer researchers in the field of oncology. It is a peer-reviewed, free website to read about news from researches and discoveries on cancer, and its founders made it open-access so that information regarding cancer and the newly discovered treatments will be available for everyone.
The most practical part of the website Oncotarget, apart from being free to hop-in and start reading about the most recent news on the field, is that it does not only publish discoveries in the field of Oncology, but also other partitions of medicine. Do you want to learn more about the process of aging and the most recent discoveries in the field? You can do that. Listen to Oncotarget podcast on Stitcher.
Oncotarget aims to spread awareness to everyone that oncologists are working hard to discover cures and treatments for cancer and they are producing good results. Cancer is one of the most fatal diseases in the world, and it can hit anyone in the most unexpected way or time.
Oncotarget believes that if more people understand cancer and more people would be aware of the innovations being made to combat it, it would greatly help the development of new ways to treat the disease. This bio-medical open access journal is available online and they now have a podcast available in Stitcher, Player.FM and iTunes.
The editors-in-chief of Oncotarget themselves are two of the most renowned in the field of oncology, and they are Mikhail Blagosklonny and Andrei V. Gudkov.
These two have spent their lives researching and developing ways to cure cancer, and they’ve achieved great discoveries already.
Dr. Gudkov is known for his work on photodynamic therapy, DNA damage, and, most of all, DNA repair, as well as thermal and hypoxic stress. Mikhail Blagosklonny, on the other hand, is known for his work with Rapamycin, now considered a wonder drug in the field of oncology because of the dozens of uses that they have for the drug.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Rapamycin has significant anti-proliferative properties that prevent cancer cells from spreading to other tissues of the body. It is also a very effective drug to use for immune-suppression during organ transplant surgeries because it prevents the immune system from rejecting the new organ.
The works of Mikhail Blagosklonny, Andre V. Gudkov, as well as other very talented and passionate oncologists, are extensively featured in Oncotarget. Learn more at researchgate.net